Adalta Ltd has released a press release.
Commercial agreement with XL-protein
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from AdAlta
- Conference Presentation
- Results of multi-dose toxicology study
- AdAlta awarded SIEF grant
- Toxicology study and manufacturing update
- Presentation of Eye Fobrosis Data at ARVO Meeting
Later from AdAlta
- AdAlta granted key Australian Patent
- AdAlta collaborator awarded NHMRC grant
- AdAlta to advance improved lung fibrosis therapy, AD-214
- Appendix 4C - Quarter Ended 31 March 2018
- AdAlta secures key manufacturing agreements for AD-214
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta